Wealthfront Advisers LLC Acquires Shares of 43,835 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wealthfront Advisers LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 43,835 shares of the biopharmaceutical company’s stock, valued at approximately $2,096,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. Parkside Financial Bank & Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. bought a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $127,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on HALO. Benchmark reaffirmed a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $62.27 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The firm’s 50 day moving average price is $56.76 and its two-hundred day moving average price is $54.76. The firm has a market cap of $7.67 billion, a P/E ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.